HC Wainwright Issues Pessimistic Outlook for SNDX Earnings

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) – Analysts at HC Wainwright dropped their Q3 2026 earnings per share estimates for Syndax Pharmaceuticals in a report issued on Thursday, October 1st. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($0.53) per share for the quarter, down from their previous estimate of ($0.48). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Syndax Pharmaceuticals’ current full-year earnings is ($2.03) per share. HC Wainwright also issued estimates for Syndax Pharmaceuticals’ Q4 2026 earnings at ($0.50) EPS, FY2026 earnings at ($2.07) EPS, FY2027 earnings at ($0.79) EPS, FY2028 earnings at $0.10 EPS, FY2029 earnings at $1.53 EPS and FY2030 earnings at $2.39 EPS.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Tuesday, August 4th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.10). Syndax Pharmaceuticals had a negative net margin of 87.52% and a negative return on equity of 372.94%. The firm had revenue of $72.79 million during the quarter, compared to analyst estimates of $79.36 million. During the same period last year, the company posted ($0.83) EPS. The firm’s revenue for the quarter was up 91.8% on a year-over-year basis.

Several other equities analysts also recently weighed in on SNDX. Bank of America restated a “buy” rating on shares of Syndax Pharmaceuticals in a report on Wednesday, August 5th. UBS Group reiterated a “buy” rating on shares of Syndax Pharmaceuticals in a research report on Thursday, October 1st. Weiss Ratings upgraded Syndax Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. JPMorgan Chase & Co. cut their price objective on Syndax Pharmaceuticals from $44.00 to $40.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $35.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, September 29th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $41.80.

Syndax Pharmaceuticals Price Performance

Syndax Pharmaceuticals stock opened at $17.37 on Monday. Syndax Pharmaceuticals has a 52 week low of $12.99 and a 52 week high of $25.59. The company has a quick ratio of 6.44, a current ratio of 6.77 and a debt-to-equity ratio of 38.95. The firm’s 50-day simple moving average is $19.17 and its 200 day simple moving average is $20.67. The firm has a market capitalization of $1.54 billion, a PE ratio of -6.92 and a beta of 0.42.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Hedge funds have recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of Syndax Pharmaceuticals during the 2nd quarter valued at about $197,177,000. Bank of America Corp DE acquired a new stake in shares of Syndax Pharmaceuticals in the second quarter worth approximately $88,426,000. Elmind Capital LP acquired a new stake in shares of Syndax Pharmaceuticals in the second quarter worth approximately $40,550,300. Trails Edge Capital Partners LP purchased a new stake in Syndax Pharmaceuticals in the second quarter valued at approximately $24,264,600. Finally, Bank of New York Mellon Corp purchased a new stake in Syndax Pharmaceuticals in the second quarter valued at approximately $22,736,000.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company’s research programs target biological pathways involved in malignancy and immune-related conditions, with an emphasis on medicines that may address significant unmet medical needs.

Syndax’s lead product, Revuforj (revumenib), is an oral menin inhibitor approved by the U.S. Food and Drug Administration for treating relapsed or refractory acute leukemia with a KMT2A translocation in adults and pediatric patients aged one year and older.